These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7852890)

  • 1. 19-Hydroxyandrostenedione amplifies the hypertensive action of mineralocorticoids in rats.
    Sekihara H; Yazaki Y; Kojima T
    J Endocrinol; 1993 Jul; 138(1):31-40. PubMed ID: 7852890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 19-hydroxyandrostenedione as a new hypertensinogenic agent.
    Sekihara H
    J Steroid Biochem; 1982 Feb; 16(2):329-31. PubMed ID: 7043093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ouabain as an amplifier of mineralocorticoid-induced hypertension.
    Sekihara H; Yazaki Y; Kojima T
    Endocrinology; 1992 Dec; 131(6):3077-82. PubMed ID: 1446641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A reevaluation of the mineralocorticoid and hypertensinogenic potential of 19-hydroxyandrostenedione.
    Gomez-Sanchez EP; Gomez-Sanchez CE
    Endocrinology; 1986 Jun; 118(6):2582-7. PubMed ID: 3698922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 19-Hydroxyandrostenedione: evidence for a new class of sodium-retaining and hypertensinogenic steroids.
    Sekihara H
    Endocrinology; 1983 Sep; 113(3):1141-8. PubMed ID: 6347666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 19-Hydroxyandrostenedione: a potent hypertensinogenic steroid in man.
    Sekihara H
    J Steroid Biochem; 1983 Jul; 19(1A):353-8. PubMed ID: 6310235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A comparative study of C19 steroid-induced hypertension and deoxycorticosterone acetate (DOCA)-salt hypertension].
    Minato M; Honda M; Hatano M
    Nihon Naibunpi Gakkai Zasshi; 1990 Jan; 66(1):29-41. PubMed ID: 2307256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of the hypertensinogenic action of 19-hydroxyandrostenedione by aromatase inhibitor, delta 1-testololactone.
    Sekihara H; Yonemitsu K; Takaku F
    Endocrinology; 1987 Dec; 121(6):1931-6. PubMed ID: 3678133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Studies on the pressor mechanism of 19-hydroxyandrostenedione].
    Honda M; Minato M; Takayama R; Nagashima Y; Watanabe M; Izumi Y; Fukuda N; Soma M; Shiratsuchi T; Watanabe Y
    Nihon Naibunpi Gakkai Zasshi; 1989 Jan; 65(1):18-31. PubMed ID: 2524410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6 beta-Hydroxyandrostenedione: evidence for a new hypertensinogenic agent.
    Sekihara H
    Clin Exp Hypertens A; 1983; 5(1):1-9. PubMed ID: 6339119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 19-Oxoandrost-4-ene-3,17-dione amplifies the action of aldosterone.
    Sekihara H; Yazaki Y
    J Steroid Biochem Mol Biol; 1993 Jul; 46(1):69-72. PubMed ID: 8338792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of arterial serotonin 1B and 2B receptors in deoxycorticosterone acetate-salt hypertension.
    Banes AK; Watts SW
    Hypertension; 2002 Feb; 39(2 Pt 2):394-8. PubMed ID: 11882579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A comparative study of C19 steroid-induced hypertension and deoxycorticosterone acetate (DOCA)-salt hypertension].
    Manabe R; Honda M; Hatano M
    Nihon Naibunpi Gakkai Zasshi; 1984 Nov; 60(11):1328-37. PubMed ID: 6526083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digoxin amplifies the effects of deoxycorticosterone acetate (DOCA) in intact water-drinking rats: implications for the mechanism of DOCA hypertension?
    Li M; Martin A; Liu DT; Whitworth JA
    J Hypertens; 1994 May; 12(5):569-76. PubMed ID: 7930557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
    Klanke B; Cordasic N; Hartner A; Schmieder RE; Veelken R; Hilgers KF
    Nephrol Dial Transplant; 2008 Nov; 23(11):3456-63. PubMed ID: 18515791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoids upregulate arterial contraction to epidermal growth factor.
    Florian JA; Dorrance A; Webb RC; Watts SW
    Am J Physiol Regul Integr Comp Physiol; 2001 Sep; 281(3):R878-86. PubMed ID: 11507004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertensinogenic potencies of aldosterone and deoxycorticosterone in the rat.
    Komanicky P; Melby JC
    Hypertension; 1982; 4(1):140-5. PubMed ID: 7061121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the Sabra hypertension-prone rat represent a model of salt or mineralocorticoid sensitivity?
    Yagil Y; Yagil C
    J Hypertens; 1998 Oct; 16(10):1481-4. PubMed ID: 9814619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of serotonin antagonists on blood pressure in mineralocorticoid hypertensive sheep.
    Mecca TE; Mitchell J; Bohr DF; Webb RC
    J Cardiovasc Pharmacol; 1985; 7(4):660-5. PubMed ID: 2410705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5 alpha-Dihydro-11-deoxycorticosterone as a mineralocorticoid agonist and antagonist: evidence for a weak mineralocorticoid as an antagonist of potent mineralocorticoids.
    Sekihara H; Yazaki Y
    J Steroid Biochem Mol Biol; 1993 Apr; 45(4):235-8. PubMed ID: 8499332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.